Prognostic significance of long noncoding RNA TTN-AS1 in various malignancies.
TTN-AS1
biomarker
cancer
meta-analysis
prognosis
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
14
06
2023
received:
19
04
2023
accepted:
30
06
2023
medline:
27
10
2023
pubmed:
2
8
2023
entrez:
2
8
2023
Statut:
ppublish
Résumé
Increasing evidence has demonstrated that high TTN-AS1 expression is highly related to poor prognosis in diverse human cancers. However, the findings concerning the prognostic value of TTN-AS1 were inconsistent, as these conclusions were usually drawn with relatively small sample sizes. Hence, this meta-analysis proposes to investigate the prognostic significance of TTN-AS1 in multiple malignancies systematically. Web of Science, Springer, Embase, PubMed, Cochrane Library, and Scopus databases were comprehensively searched to retrieve studies related to the TTN-AS1 expression with the prognosis of malignancies. The significance of the TTN-AS1 in cancers was estimated by hazard ratios (HRs) or odds ratios (ORs). Additionally, the Gene Expression Profiling Interactive Analysis (GEPIA) analysis tool was used to strengthen our results further. Twenty studies involving 17 different cancers and 1330 patients were recruited into this meta-analysis. The research revealed that high TTN-AS1 expression was remarkably associated with unfavorable overall survival (OS) (HR = 2.07, 95%CI [1.78, 2.41], p < .00001) when compared with low TTN-AS1 expression in malignancies. Additionally, elevated TTN-AS1 expression significantly contributed to lymph node metastasis (OR = 4.09, 95%CI [3.08, 5.44], p < .0001), larger tumor size (OR = 2.42, 95%CI [1.56, 3.77], p < .0001), worse tumor differentiation (OR = 0.36, 95%CI [0.22, 0.59], p < .0001) and more advanced tumor stage (OR = 0.29, 95%CI [0.22, 0.38], p < .0001) with low or no heterogeneity existing. Moreover, high TTN-AS1 expression was connected with worse disease-free survival in five different cancers based on the GEPIA online database. The results of this meta-analysis support that high TTN-AS1 expression significantly correlates with worse prognosis in various cancers. Therefore, TTN-AS1 may be considered as a novel biomarker for malignancies.
Sections du résumé
BACKGROUND
Increasing evidence has demonstrated that high TTN-AS1 expression is highly related to poor prognosis in diverse human cancers. However, the findings concerning the prognostic value of TTN-AS1 were inconsistent, as these conclusions were usually drawn with relatively small sample sizes. Hence, this meta-analysis proposes to investigate the prognostic significance of TTN-AS1 in multiple malignancies systematically.
METHODS
Web of Science, Springer, Embase, PubMed, Cochrane Library, and Scopus databases were comprehensively searched to retrieve studies related to the TTN-AS1 expression with the prognosis of malignancies. The significance of the TTN-AS1 in cancers was estimated by hazard ratios (HRs) or odds ratios (ORs). Additionally, the Gene Expression Profiling Interactive Analysis (GEPIA) analysis tool was used to strengthen our results further.
RESULTS
Twenty studies involving 17 different cancers and 1330 patients were recruited into this meta-analysis. The research revealed that high TTN-AS1 expression was remarkably associated with unfavorable overall survival (OS) (HR = 2.07, 95%CI [1.78, 2.41], p < .00001) when compared with low TTN-AS1 expression in malignancies. Additionally, elevated TTN-AS1 expression significantly contributed to lymph node metastasis (OR = 4.09, 95%CI [3.08, 5.44], p < .0001), larger tumor size (OR = 2.42, 95%CI [1.56, 3.77], p < .0001), worse tumor differentiation (OR = 0.36, 95%CI [0.22, 0.59], p < .0001) and more advanced tumor stage (OR = 0.29, 95%CI [0.22, 0.38], p < .0001) with low or no heterogeneity existing. Moreover, high TTN-AS1 expression was connected with worse disease-free survival in five different cancers based on the GEPIA online database.
CONCLUSIONS
The results of this meta-analysis support that high TTN-AS1 expression significantly correlates with worse prognosis in various cancers. Therefore, TTN-AS1 may be considered as a novel biomarker for malignancies.
Identifiants
pubmed: 37528740
doi: 10.1002/cnr2.1876
pmc: PMC10598252
doi:
Substances chimiques
RNA, Long Noncoding
0
Biomarkers, Tumor
0
TTN protein, human
0
Connectin
0
Types de publication
Meta-Analysis
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1876Informations de copyright
© 2023 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
J Cell Biochem. 2020 Feb 26;:
pubmed: 32100921
Oncol Rep. 2020 Oct;44(4):1343-1354
pubmed: 32945477
Life Sci. 2020 Mar 1;244:116936
pubmed: 31610194
Bioengineered. 2021 Dec;12(1):578-588
pubmed: 33517826
Biochem Biophys Res Commun. 2018 Sep 18;503(4):2956-2962
pubmed: 30135013
Mol Ther Oncolytics. 2021 Nov 24;24:535-546
pubmed: 35229031
Aging (Albany NY). 2019 Sep 16;11(18):7678-7693
pubmed: 31525734
Mol Ther Nucleic Acids. 2020 Mar 6;19:905-921
pubmed: 32000032
Bioengineered. 2021 Dec;12(1):7724-7736
pubmed: 34606420
Onco Targets Ther. 2019 Dec 27;12:11531-11539
pubmed: 31920341
Cell Death Dis. 2020 Aug 15;11(8):637
pubmed: 32801339
Oncol Lett. 2021 Nov;22(5):794
pubmed: 34584569
Nat Med. 2022 Apr;28(4):649-657
pubmed: 35440716
Nucleic Acids Res. 2022 Jan 7;50(D1):D1295-D1306
pubmed: 34791419
Chem Soc Rev. 2015 May 21;44(10):2963-97
pubmed: 25739971
Biomed Pharmacother. 2021 Jan;133:111030
pubmed: 33378944
Front Genet. 2021 Oct 04;12:704712
pubmed: 34671381
Front Oncol. 2022 Jul 19;12:963617
pubmed: 35928868
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Brief Bioinform. 2020 Dec 1;21(6):2175-2184
pubmed: 31814027
Semin Cancer Biol. 2021 Oct;75:38-48
pubmed: 33346133
Oncol Rep. 2020 Sep;44(3):1064-1074
pubmed: 32705233
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Cell Death Dis. 2020 Aug 20;11(8):664
pubmed: 32820147
Trials. 2007 Jun 07;8:16
pubmed: 17555582
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Cell Biochem. 2019 Oct;120(10):17131-17141
pubmed: 31173403
Eur Rev Med Pharmacol Sci. 2019 Sep;23(18):7816-7825
pubmed: 31599406
Sci Rep. 2022 Jul 1;12(1):11161
pubmed: 35778520
Cancer Rep (Hoboken). 2023 Oct;6(10):e1876
pubmed: 37528740
Onco Targets Ther. 2020 Jul 01;13:6361-6371
pubmed: 32669856
Biomed Pharmacother. 2021 Mar;135:111169
pubmed: 33433359
Nat Rev Cancer. 2020 Jun;20(6):303-322
pubmed: 32300195
Nat Rev Mol Cell Biol. 2016 Dec;17(12):756-770
pubmed: 27780979
Cancer Manag Res. 2020 May 04;12:3091-3097
pubmed: 32440207
Front Oncol. 2021 Jun 01;11:652835
pubmed: 34141611
J Gene Med. 2019 May;21(5):e3083
pubmed: 30811764
Neoplasma. 2019 Jul 23;66(4):564-575
pubmed: 30943745
Cell Death Dis. 2019 Jul 30;10(8):573
pubmed: 31363080
Clin Cancer Res. 2018 Jan 15;24(2):486-498
pubmed: 29101304
Biomed Res Int. 2018 Jun 26;2018:2864120
pubmed: 30046591
Onco Targets Ther. 2020 May 27;13:4799-4811
pubmed: 32547107